StreetInsider.com News Articles

Form SCHEDULE 13D/A Nautilus Biotechnology, Filed by: AH Bio Fund II, L.P.

Fri, 11 Sep 2026 17:09:00 -0400

si-local-file:///var/storage/secattach/20260911/27053628.html

Form 8-K Nautilus Biotechnology, For: Sep 11

Fri, 11 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260911/27052952.html

Nautilus Biotechnology (NAUT) files $300M mixed shelf

Fri, 11 Sep 2026 16:07:43 -0400

Nautilus Biotechnology (NASDAQ: NAUT) filed $300,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Depositary Shares
Warrants
Subscription Rights
Purchase Contracts
Units

Nautilus Biotechnology (NAUT) files $300M mixed shelf

Fri, 11 Sep 2026 16:07:43 -0400

Nautilus Biotechnology (NASDAQ: NAUT) filed $300,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Depositary Shares
Warrants
Subscription Rights
Purchase Contracts
Units

Form S-3 Nautilus Biotechnology,

Fri, 11 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260911/27052894.html

Leerink Starts Nautilus Biotechnology (NAUT) at Outperform

Wed, 09 Sep 2026 06:10:53 -0400

Leerink analyst Daniel Clark initiates coverage on Nautilus Biotechnology (NASDAQ: NAUT) with a Outperform rating and a price target of $4.00.

For an analyst ratings summary and ratings history on Nautilus Biotechnology click here. For more ratings news on Nautilus Biotechnology click here.

Shares of Nautilus Biotechnology closed at $0.93 yesterday.

Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms

Fri, 04 Sep 2026 08:00:00 -0400

First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas

Key takeaways:

Going beyond measurement of bulk tau to quantify each of the diverse proteoforms of tau is key to developing novel diagnostics and precision medicine for Alzheimer’s disease and related tauopathies.
Proteoforms – distinct forms of protein that are defined by ordered, non-random combinations of modifications – control biology and are uniquely quantifiable at scale on the Nautilus Voyager Platform.
Iterative Mapping of tau resolved 130 tau proteoform groups

Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms

Fri, 04 Sep 2026 08:00:00 -0400

Key takeaways:

Going beyond measurement of bulk tau to quantify each of the diverse proteoforms of tau is key to developing novel diagnostics and precision medicine for Alzheimer’s disease and related tauopathies.
Proteoforms – distinct forms of protein that are defined by ordered, non-random combinations of modifications – control biology and are uniquely quantifiable at scale on the Nautilus Voyager Platform.
Iterative Mapping of tau resolved 130 tau proteoform groups

Form SCHEDULE 13D/A Nautilus Biotechnology, Filed by: AH Bio Fund II, L.P.

Fri, 28 Aug 2026 19:43:00 -0400

si-local-file:///var/storage/secattach/20260828/26999373.html

Form SCHEDULE 13D/A Nautilus Biotechnology, Filed by: AH Bio Fund II, L.P.

Fri, 28 Aug 2026 19:43:00 -0400

si-local-file:///var/storage/secattach/20260828/26999373.html

Form SCHEDULE 13D/A Nautilus Biotechnology, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26932843.html

Form SCHEDULE 13D/A Nautilus Biotechnology, Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260814/26932843.html

Form 10-Q Nautilus Biotechnology, For: Jun 30

Tue, 28 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260728/26827070.html

Form 10-Q Nautilus Biotechnology, For: Jun 30

Tue, 28 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260728/26827070.html

Nautilus Biotechnology Reports Second Quarter 2026 Financial Results

Tue, 28 Jul 2026 08:00:00 -0400

SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Business Highlights

Recognized first revenue in the second quarter of 2026, including grant revenue from the Michael J. Fox Foundation supporting our alpha-synuclein proteoform assay development, together with revenue from our first Iterative Mapping Early Access Program customer.
Grew our commercial organization to three team members, including our previously announced VP of Global Sales, driving engagement with prospective

Nautilus Biotechnology Reports Second Quarter 2026 Financial Results

Tue, 28 Jul 2026 08:00:00 -0400

Second Quarter 2026 Business Highlights

Recognized first revenue in the second quarter of 2026, including grant revenue from the Michael J. Fox Foundation supporting our alpha-synuclein proteoform assay development, together with revenue from our first Iterative Mapping Early Access Program customer.
Grew our commercial organization to three team members, including our previously announced VP of Global Sales, driving engagement with prospective

Nautilus Biotechnology, Inc. (NAUT) Tops Q2 EPS by 4c

Tue, 28 Jul 2026 06:49:05 -0400

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) reported Q2 EPS of ($0.11), $0.04 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $190 thousand.

For earnings history and earnings-related data on Nautilus Biotechnology, Inc. (NAUT) click here.

Form 8-K Nautilus Biotechnology, For: Jul 28

Tue, 28 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260728/26821556.html

Form 8-K Nautilus Biotechnology, For: Jul 28

Tue, 28 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260728/26821556.html

Form SCHEDULE 13D/A Nautilus Biotechnology, Filed by: AH Bio Fund II, L.P.

Tue, 30 Jun 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260630/26714786.html

Form SCHEDULE 13D/A Nautilus Biotechnology, Filed by: AH Bio Fund II, L.P.

Tue, 30 Jun 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260630/26714786.html

Form 4 Nautilus Biotechnology, For: Jun 18 Filed by: Epperly Melissa B,

Mon, 22 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260622/26673214.html

Form 4 Nautilus Biotechnology, For: Jun 18 Filed by: Epperly Melissa B,

Mon, 22 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260622/26673214.html

Form 4 Nautilus Biotechnology, For: Jun 18 Filed by: McIlwain Matthew S

Mon, 22 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260622/26673223.html

Form 4 Nautilus Biotechnology, For: Jun 18 Filed by: McIlwain Matthew S

Mon, 22 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260622/26673223.html